We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMTX
151
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$756K 0.02%
53,186
-96,639
-65% -$1.67M
KOD icon
152
Kodiak Sciences
KOD
$2.6B
$723K 0.02%
+8,530
New +$868K
BDTX icon
153
Black Diamond Therapeutics
BDTX
$96.8M
$704K 0.02%
131,990
– –
CHCT
154
Community Healthcare Trust
CHCT
$523M
$704K 0.02%
14,900
– –
UHT
155
Universal Health Realty Income Trust
UHT
$603M
$670K 0.02%
11,258
– –
RPTX
156
DELISTED
Repare Therapeutics
RPTX
$615K 0.02%
+29,150
New +$687K
ARDX icon
157
Ardelyx
ARDX
$1.22B
$593K 0.02%
539,408
– –
NHI icon
158
National Health Investors
NHI
$3.72B
$577K 0.02%
10,038
– –
ONEM
159
DELISTED
1Life Healthcare
ONEM
$549K 0.02%
31,266
– –
IDYA icon
160
IDEAYA Biosciences
IDYA
$3.42B
$484K 0.02%
+20,454
New +$475K
NKTX icon
161
Nkarta
NKTX
$150M
$445K 0.01%
28,988
– –
KALV
162
DELISTED
KalVista Pharmaceuticals
KALV
$418K 0.01%
31,594
-68,406
-68% -$1.09M
FUSN
163
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$181K 0.01%
43,394
– –
SPPI
164
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$146K ﹤0.01%
114,670
– –
YARW
165
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$138K ﹤0.01%
150
– –
CRBP icon
166
Corbus Pharmaceuticals
CRBP
$166M
$95K ﹤0.01%
5,144
-8,639
-63% -$234K
ALR
167
DELISTED
AlerisLife Inc
ALR
$71K ﹤0.01%
24,237
– –
ORKA
168
Oruka Therapeutics
ORKA
$5.82B
$70K ﹤0.01%
2,705
– –
BLCM
169
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$9K ﹤0.01%
6,000
– –
BOLT icon
170
Bolt Biotherapeutics
BOLT
$7.67M
– –
-3,251
Closed -$823K
CDXS icon
171
Codexis
CDXS
$151M
– –
-80,448
Closed -$1.87M
EXAS
172
DELISTED
Exact Sciences
EXAS
– –
-225,282
Closed -$21.5M
FOLD
173
DELISTED
Amicus Therapeutics
FOLD
– –
-587,277
Closed -$5.61M
KURA icon
174
Kura Oncology
KURA
$800M
– –
-273,463
Closed -$5.12M
OGN icon
175
Organon & Co
OGN
$3.56B
– –
-3,717
Closed -$122K
4 5 6
7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.